Lim-Fat Mary Jane, Bennett Julie, Ostrom Quinn, Touat Mehdi, Franceschi Enrico, Schulte Jessica, Bindra Ranjit S, Fangusaro Jason, Dhall Girish, Nicholson James, Jackson Sadhana, Davidson Tom Belle, Calaminus Gabriele, Robinson Giles, Whittle James R, Hau Peter, Ramaswamy Vijay, Pajtler Kristian W, Rudà Roberta, Foreman Nicholas K, Hervey-Jumper Shawn L, Das Sunit, Dirks Peter, Bi Wenya Linda, Huang Annie, Merchant Thomas E, Fouladi Maryam, Aldape Kenneth, Van den Bent Martin J, Packer Roger J, Miller Julie J, Reardon David A, Chang Susan M, Haas-Kogan Daphne, Tabori Uri, Hawkins Cynthia, Monje Michelle, Wen Patrick Y, Bouffet Eric, Yeo Kee Kiat
Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Ontario, Canada.
Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Neuro Oncol. 2025 Jan 12;27(1):13-32. doi: 10.1093/neuonc/noae186.
Adolescents and young adults (AYAs; ages 15-39 years) are a vulnerable population facing challenges in oncological care, including access to specialized care, transition of care, unique tumor biology, and poor representation in clinical trials. Brain tumors are the second most common tumor type in AYA, with malignant brain tumors being the most common cause of cancer-related death. The 2021 WHO Classification for central nervous system (CNS) Tumors highlights the importance of integrated molecular characterization with histologic diagnosis in several tumors relevant to the AYA population. In this position paper from the Society for Neuro-Oncology (SNO), the diagnosis and management of CNS tumors in AYA is reviewed, focusing on the most common tumor types in this population, namely glioma, medulloblastoma, ependymoma, and CNS germ cell tumor. Current challenges and future directions specific to AYA are also highlighted. Finally, possible solutions to address barriers in the care of AYA patients are discussed, emphasizing the need for multidisciplinary and collaborative approaches that span the pediatric and adult paradigms of care, and incorporating advanced molecular testing, targeted therapy, and AYA-centered care.
Cochrane Database Syst Rev. 2016-6-27
Curr Neurol Neurosci Rep. 2025-7-1
Curr Cancer Drug Targets. 2025-6-30
Cochrane Database Syst Rev. 2012-12-12
Cochrane Database Syst Rev. 2024-10-9
Health Technol Assess. 2024-10
Diagnostics (Basel). 2025-8-10
Curr Neurol Neurosci Rep. 2025-8-12
N Engl J Med. 2023-9-21